|
Oct 1
|
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
|
|
Sep 27
|
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
Sep 8
|
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
|
|
Jun 26
|
Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
Jun 26
|
Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
May 9
|
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 7
|
Savara to Present at the Citizens JMP Life Sciences Conference
|
|
Apr 8
|
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
|
|
Mar 22
|
Savara Announces New Employment Inducement Grant
|
|
Mar 7
|
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update
|
|
Mar 6
|
Savara to Present at the Barclays 26th Annual Global Healthcare Conference
|
|
Feb 20
|
Savara Inc. (NASDAQ:SVRA): Are Analysts Optimistic?
|
|
Dec 30
|
Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA)
|
|
Dec 21
|
Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
|
Dec 20
|
Savara Added to the NASDAQ Biotechnology Index
|
|
Dec 1
|
Savara Inc. (NASDAQ:SVRA) most popular amongst private equity firms who own 41% of the shares, institutions hold 31%
|
|
Sep 5
|
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|